Cephalon reaches $1 billion milestone in annual revenue

02/17/2005 | Philadelphia Inquirer, The

Cephalon's announcement puts it in a league with only eight other U.S. biotechnology companies, and the firm's CEO said he expects revenues to double to $2 billion by the end of 2008. In the coming two years, Cephalon faces a loss of patent for two of its biggest products, Provigil and Actiq, and one analyst said the company would need to "ramp up sales in the attention-deficit market" and get approval of another drug now in Phase III clinical trials to offset the expected generic competition for Provigil and Actiq.

View Full Article in:

Philadelphia Inquirer, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD